share_log

PureTech Completes Enrollment In Phase 2b ELEVATE IPF Trial Of LYT-100 (Deupirfenidone) In Idiopathic Pulmonary Fibrosis; Topline Results Expected In Q4 Of 2024

Benzinga ·  Apr 16 19:04
PureTech Completes Enrollment In Phase 2b ELEVATE IPF Trial Of LYT-100 (Deupirfenidone) In Idiopathic Pulmonary Fibrosis; Topline Results Expected In Q4 Of 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment